Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects

Phase 1 Completed 24 enrolled UCB Pharma

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to characterize the Pharmacokinetics (PK) of unconjugated and total Rotigotine after single and multiple doses of Rotigotine transdermal patch, and also to investigate the safety and tolerability of Rotigotine transdermal patch in healthy Chinese subjects.

Timeline

Start: 2012-08
Primary completion: 2012-09
Completion: 2012-09

Publications

Liu Y, Tomlinson B, Guo J, Asgharnejad M, Bauer L, Surmann E, Guo X, Elshoff JP. Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects. Clin Ther. 2018 Jul;40(7):1108-1121.e8. doi: 10.1016/j.clinthera.2018.05.009.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotigotine	Unknown	2 mg	Other
Subject	Rotigotine	Unknown	4 mg	Other

Indications

No indication recorded.